News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Data from Two Phase III Studies of Merck & Co., Inc. (MRK)'s Investigational Asthma Drug Presented at American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting



3/2/2010 10:34:47 AM

NEW ORLEANS--(BUSINESS WIRE)--Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES